HC Wainwright Reiterates Buy Rating for Phio Pharmaceuticals (NASDAQ:PHIO)

HC Wainwright reissued their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) in a report published on Wednesday morning, Marketbeat reports. They currently have a $6.00 target price on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2023 earnings at ($1.43) EPS, Q4 2023 earnings at ($0.81) EPS, FY2023 […]

Related Keywords

United States ,Montreal ,Quebec ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom , ,Institutional Investors Weigh In On Phio Pharmaceuticals ,Cambridge Investment Research Advisors Inc ,Phio Pharmaceuticals Stock ,News Ratings For Phio Pharmaceuticals Daily ,Phio Pharmaceuticals Corp ,Phio Pharmaceuticals ,Vanguard Group Inc ,Phio Pharmaceuticals Company Profile ,Free Report ,Montreal Can ,Investment Advisers ,Investment Research Advisors ,Anson Funds Management ,Get Free Report ,Natural Killer ,Phio Pharmaceuticals Daily ,Nasdaq Phio ,Ephio ,Medical ,Reiterated Rating ,Hc Wainwright ,